REVIEW ONCOLOGY

The role of radiation therapy in pancreatic cancer management

BJMO - volume 16, issue 7, november 2022

I. Joye MD, PhD, N. Meireson MD, R. Weytjens MD, S. Vanderkam MD

SUMMARY

Treatment of pancreatic ductal adenocarcinoma (PDAC) has been the subject of controversy for decades. At the centre of this controversy is radiation therapy. Since PDAC is considered a systemic disease, the role of radiation therapy is debated. However, most of the available evidence is blurred by suboptimal radiation doses, less effective chemotherapy regimens and abandoned radiotherapy techniques. This article reviewed the available literature and discussed the changes in radiation therapy that have taken place over the past decade.

(BELG J MED ONCOL 2022;16(7):328–35)

Read more

Radiotherapy for metastatic colorectal cancer: When is it worth it?

BJMO - volume 16, issue 7, november 2022

K. Haustermans MD, PhD, P. Populaire MD, S. Isebaert PhD

SUMMARY

Colorectal cancer is a prevalent cancer in Belgium. Unfortunately, many of these patients will develop metastases at some point in their disease. However, given the new therapeutic options, the prognosis of these patients is better than before. Local ablation of metastases is among these therapeutic options. This concept of metastasis-directed therapy (MDT) is generally accepted for oligometastatic disease. It can be accomplished by a multitude of techniques, including surgery, radiofrequency and microwave ablation, but also radiotherapy (RT). This review addressed the rationale and application of RT within this context.

(BELG J MED ONCOL 2022;16(7):336–42)

Read more

Tailoring systemic treatment after neoadjuvant chemotherapy in patients with early breast cancer

BJMO - volume 16, issue 6, october 2022

D. Martins-Branco MD, E. Agostinetto MD, E. de Azambuja MD, PhD, G. Nader-Marta MD, V. Debien MD

SUMMARY

Neoadjuvant treatments in patients with breast cancer provide the opportunity for a direct evaluation of treatment effect on tumour size, allow higher rates of conservative surgery and give the chance to tailor systemic treatments after surgery. Patients who achieve a pathological complete response experience better long-term survival, compared to those with residual disease after the completion of neoadjuvant therapy, and those with residual invasive disease at surgery may benefit from additional post-neoadjuvant treatment strategies. Some systemic post-neoadjuvant treatments for patients with residual disease at surgery are already approved in clinical practice (i.e., capecitabine for patients with triple-negative breast cancer, or T-DM1 for patients with HER2-positive disease), and several new strategies are currently under evaluation. The present review discusses the available evidence for the implementation of systemic post-neoadjuvant treatment strategies into clinical practice for patients with early breast cancer, shading light on the pitfalls and limitations of different studies, and summarising data on novel promising treatment strategies that are being explored in clinical trials.

(BELG J MED ONCOL 2022;16(6):262–73)

Read more

The impact of sarcopenia in oncology Patients

BJMO - volume 16, issue 6, october 2022

C. van Marcke MD, L. Duck MD, N. Baczewska MD, R. Poncin MD

SUMMARY

Sarcopenia is defined as the loss of muscle mass and strength and plays an increasingly important role in the management of oncology patients. Sarcopenia is frequently mislabelled as malnutrition or cachexia. Clinicians lack a consensus definition of easy-to-use, straightforward, reliable diagnostic tools to optimally recognise sarcopenia. This review will broadly go through the current literature in order to define sarcopenia, as well as to understand its mechanisms. Helpful diagnostic tools will be discussed, which can be used to optimise the management of patients suffering from a malignant disease. This review will also illustrate how sarcopenia is an independent negative predictive and prognostic factor regarding survival and quality of life, directly impacting toxicity and efficacy of oncological treatments.

(BELG J MED ONCOL 2022;16(6):274–8)

Read more

Lung cancer screening in 2022: How should we screen optimally?

BJMO - volume 16, issue 6, october 2022

A. Snoeckx MD, PhD, J.P. Van Meerbeeck MD, PhD

SUMMARY

On the brink of the implementation of lung cancer screening, the road from a controlled clinical trial to the real world is long, winding and not without hurdles. The latter will be addressed to come to an optimal lung cancer screening environment in Belgium.

(BELG J MED ONCOL 2022;16(6):279–86)

Read more

Bone health in cancer

BJMO - volume 16, issue 4, june 2022

D. Schrijvers MD, PhD

Bone health is an important factor in the quality of life of cancer patients. Complications of impaired bone health can impact the quality of life and the survival of these patients. Every oncologist should look at problems of bone health such as osteoporosis and complications related to patient characteristics, the oncological disease and the cancer treatment. Complications should be prevented and, if they occur, adequately treated.

(BELG J MED ONCOL 2022;16(4):161–5)

Read more

Escalation and de-escalation strategies in early breast cancer

BJMO - volume 16, issue 3, may 2022

D. Taylor MD, E. de Azambuja MD, PhD, K. Punie MD

SUMMARY

Early breast cancer is the most frequently diagnosed cancer among women worldwide. Different subtypes have been identified, and with them, new treatment strategies have emerged. In order to elaborate a personalised treatment, clinicians need reliable pathological and molecular disease subtyping, refined assessments of the risk of relapse, and predictive markers to estimate treatment benefit. Combining these elements allows for de-escalation in some patients and, on the contrary, identifies those who should receive more intensive therapy and serve as candidates for escalation strategies in standard practice or clinical trials. This article reviews the de-escalation and escalation strategies currently available and will explore future treatment perspectives in early breast cancer.

(BELG J MED ONCOL 2022;16(3):102–13)

Read more
X